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A comparison of two methods for measuring anti-hypertensive 
drug use: concordance of use with South African standard 
treatment guidelines
Thamizhanban Pillay,a Anthony J Smith a & Suzanne R Hill b
Objective To assess prescriber adherence to standard anti-hypertensive treatment guidelines in South Africa, determine if supply data 
are useful indicators of drug use, and assess the cost implications of not complying with the guidelines.
Methods We undertook two studies: an analysis of records of the anti-hypertensive drugs supplied to all 54 public-sector hospitals 
with a hypertension clinic in KwaZulu-Natal, and a direct-observation survey of anti-hypertensive drug prescriptions presented to 
pharmacies in a subset of 16 of the 54 hospitals. We calculated the relative use of each anti-hypertensive drug group as a proportion 
of all anti-hypertensive drugs supplied or prescribed. We ranked drug groups in order of use for comparison with recommended 
South African standard treatment guidelines, and we compared the proportions derived from supply data with those derived from 
the prescription survey.
Findings Supply data showed that, in line with treatment guidelines, diuretics and angiotensin-converting enzyme inhibitors were the 
most frequently supplied medicines (42% and 27%, respectively). However, methyldopa – not included in the treatment guidelines – 
represented 10% of all anti-hypertensives supplied, but the proportion varied widely between hospitals (0–37%). Reserpine, second 
choice in the treatment guidelines, was used in high amounts by only two hospitals. Calcium channel blockers and beta blockers 
represented a small proportion of the anti-hypertensive drugs supplied: 6% each. Results from the prescription survey were in 
concordance with supply data for the most frequently prescribed drugs but gave slightly different estimates of the use of others.
Conclusion Supply data, the most available source of information about drug use in developing countries, are (with some provisos) 
a reliable data source for the evaluation of adherence to treatment guidelines. Our results showed substantial non-adherence to 
standard treatment guidelines.
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Introduction
In 1994, the new South African Government of National 
Unity formulated a national drug policy based on standards 
for national medicines polices advocated by WHO.1 Imple-
mentation strategies included the development of a list of 
essential medicines and the compilation of evidence-based 
standard treatment guidelines for common disorders, includ-
ing hypertension, to be adopted throughout South Africa’s 
public sector.
According to the results of the first Demographic Health 
Survey in South Africa in 1998, hypertension is the most 
prevalent chronic health condition reported by men and 
women across all provinces. With more than 80% of the 
South African population receiving care through the public 
health system, these guidelines can have a significant impact 
on the nation’s health care. However, follow-up evaluation 
of hypertension guidelines 4 years and 5 years after their 
introduction by means of hospital prescription surveys sug-
gested that the recommendations were not being followed.2,3 
In an unpublished study in outpatients attending a hospital 
hypertension clinic in the province of KwaZulu-Natal in 1999, 
one-third of the 1288 prescriptions surveyed were for meth-
yldopa, even though this drug was not recommended in the 
guidelines except during pregnancy. This finding mirrored 
those of Edwards et al.,4 who noted that 28% of patients with 
hypertension at a community health centre were prescribed 
methyldopa.
We wanted to examine the extent to which hospital 
prescribers followed the guidelines in their everyday work. 
We therefore undertook further studies of drug prescription 
patterns in South African public hospitals.
Quantitative drug-use studies can take several forms.5,6 
Rarely is it possible to measure the actual consumption of 
medicines by patients. More commonly, the number of pre-
scriptions issued is assumed to reflect actual use.
In settings where prescriptions are recorded on an elec-
tronic database that also includes the indication for the drug, 
prescription data may be readily obtained and matched to 
the indication. However, in most of South Africa, and in 
developing countries in general, such electronic records are 
not available, and drug-use data must be obtained by direct 
survey, a laborious and time-intensive process.
More sophisticated methods for linking prescription to 
indication make connections between large databases (e.g. 
those of Health Maintenance or other administrative organi-
zations in the United States of America).7 What such methods 
lack in precision they make up in quantity, but they are cur-
rently beyond the means of most developing countries.
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As a preliminary assessment of 
prescribers’ adherence to South African 
standard treatment guidelines for hy-
pertension, we compared data from 
records of medicine supply to hospitals 
(supply data) with data from direct 
observation of prescriptions presented 
to hospital pharmacies. Even though 
supply data from a central depot to 
hospitals are acknowledged to be only 
an approximation of prescription data, 
they are readily obtainable worldwide 
and provide an indication of trends in 
drug use. Few studies have compared 
these two sources.
Specifically, in this study we pur-
sued several objectives: (i) to identify 
the relative use of anti-hypertensive 
drugs using data from records of drugs 
supplied to hospitals and a survey of 
prescriptions presented to hospital 
pharmacies; (ii) to determine whether 
supply data are useful indicators of 
drug use by comparing them with 
data derived from direct observation 
(i.e. the prescription survey); (iii) to 
compare prescribing patterns for anti-
hypertensive drugs with standard treat-
ment guidelines; and (iv) to determine 
the cost implications of non-compliance 
with the guidelines.
Methods
Drug supply data
All 63 public-sector hospitals in Kwa-
Zulu-Natal purchase pharmaceuticals 
from a central store, the provincial 
medical supply centre (PMSC). The 
PMSC is responsible for purchasing, 
storing, pre-packing and delivering 
drugs to all public hospitals in the prov-
ince. To minimize work at the hospitals, 
PMSC supplies most drugs in patient-
ready packs (PRPs) that contain a pre-
packaged volume of tablets, capsules or 
liquid sufficient for 28 days of therapy.
All drugs available from the PMSC 
are listed on an official catalogue which 
has been approved by the provincial 
Pharmacy and Therapeutics Committee. 
The volume and value of drugs supplied 
to each hospital are recorded on the 
PMSC database, along with information 
about the dosage, pack size and cost of 
each drug supplied. Nine of the 63 hos-
pitals in KwaZulu-Natal were excluded 
from the study because they did not offer 
an outpatient clinic service to patients 
with hypertension.
The PMSC catalogue was used 
to identify all anti-hypertensive drugs 
supplied in the province. The catalogue 
numbers for these drugs were used to 
generate a report of the volume of drugs 
supplied to hospitals over a 6-month 
period. Most anti-hypertensive drugs 
are supplied in 28-day PRPs, except for 
a few bulk packs that are supplied to 
hospitals with facilities for repacking the 
drugs. Pharmacy managers at hospitals 
that ordered bulk packs were contacted 
and asked about the size of the packs 
being dispensed to patients at their in-
stitution, and they confirmed that they 
issued standard 28-day packs.
The total number of PRPs was 
calculated in three steps. First, the total 
number of PRPs of each anti-hypertensive 
agent supplied to each hospital over a 
6-month period was taken to reflect 
the total number of units of each anti-
hypertensive prescribed. For example, 
if a hospital was supplied 10 000 PRPs 
of hydrochlorothiazide tablets during 
6 months, we assumed this represented 
10 000 prescriptions for hydrochloro-
thiazide tablets.
Second, the PRPs of the anti-
hypertensive drugs were divided into 
pharmacological groups: diuretics (hy-
drochlorothiazide, indapamide), beta 
blockers (atenolol, propranolol), calcium 
channel blockers (isradipine, nifedipine, 
amlodipine, verapamil, diltiazem), 
angiotensin-converting enzyme (ACE) 
inhibitors (captopril, perindopril), 
methyldopa, reserpine, hydralazine and 
prazosin. Finally, the sum of the PRPs 
of all individual drug groups was cal-
culated to represent the total number 
of PRPs for all anti-hypertensive drugs 
supplied over the 6-month period.
Methyldopa as an indicator
Methyldopa use was selected as an ini-
tial indicator of non-adherence to the 
hypertension treatment guidelines. We 
calculated the amount of methyldopa 
supplied to each hospital as a propor-
tion of all the anti-hypertensive drugs 
supplied over a 6-month period (total 
number of PRPs of methyldopa divided 
by total PRPs of all anti-hypertensive 
agents). We calculated the overall pro-
portion of methyldopa from the mean 
proportion used in each hospital rather 
than by pooling all the data.
To assess whether our 6-month sup-
ply data was representative of longer-
term methyldopa use, we compared 
the number of PRPs supplied each year 
from 1997 to 2001 with the number 
supplied in 1997. Overall, methyldopa 
supply had decreased from 1997 but 
had stabilized during the 2 years before 
the prescription survey.
Prescription survey
The second part of the study was a survey 
of anti-hypertensive prescriptions at 16 
hospitals. To provide an approximate 
indicator of compliance with treatment 
guidelines, we used supply data to cat-
egorize hospitals into usage groups: low 
(< 5% of all anti-hypertensives supplied), 
intermediate (5–12%) and high (> 12%).
We selected five institutions from 
each category of methyldopa use and 
included urban and rural hospitals 
from across the province. Permission 
to conduct the study was requested 
from hospital superintendents in the 
selected institutions, and hospitals that 
did not respond were followed up with 
telephone reminders.
We visited superintendents to ex-
plain the survey procedure. One of the 
hospitals that failed to respond initially 
requested participation at the end of 
the recruitment period. Therefore, 16 
hospitals were included in the prescrip-
tion survey – 8 urban and 8 rural. This 
was a pragmatic, rather than a random, 
sample of the larger group of 54 hospi-
tals included in the supply data study.
Hospitals were visited on the day 
allocated for treatment of outpatients 
with hypertension, and the prescrip-
tion survey took place in the hospital 
pharmacy department. Consecutive, 
original prescriptions (new and repeats) 
presented to the outpatient pharmacy 
department for the management of un-
complicated essential hypertension were 
used to record the names and doses of 
all anti-hypertensive drugs prescribed. 
We did not record any prescriber infor-
mation or patient names. Prescriptions 
were attached to the clinical notes, so 
we were able to confirm the diagnosis of 
uncomplicated essential hypertension 
in all cases. Prescriptions for patients 
with co-morbid conditions were not 
included in the survey.
Statistical analysis
Regional hospital pharmacies fill ap-
proximately 3500 prescriptions for anti-
hypertensives per month, and smaller 
district hospitals fill around 1500.
In one hospital, the prescription 
rate for methyldopa was approximately 
30%, according to a survey.4 The num-
ber of prescriptions needed to detect 
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a 30% methyldopa prescription rate 
was calculated using StatsDirect (Stats-
Direct, Altrincham, England), and the 
maximum acceptable deviation of the 
sample rate from the true population 
rate was set at 10%, with a confidence 
level of 95%. The sample size required 
was 79; therefore, we included 100 pre-
scriptions at each institution.
To determine whether prescribing 
practices varied at different times of the 
day, prescriptions from one urban and 
one rural hospital were collected every 
3 hours during a hypertension clinic 
day. No differences were found in the 
prescription pattern between hospitals 
or time periods.
For each hospital we calculated the 
proportion of prescriptions for every 
drug type, as well as for monotherapy 
and combination therapy, and we re-
corded the doses prescribed. We then 
compared the results obtained with the 
two methods for measuring the use 
of anti-hypertensive drugs. To allow 
for comparisons, results are expressed 
as percentages of all prescribed anti-
hypertensives.
Ethics approval
The study was approved by the Uni-
versity of Newcastle Human Research 
Ethics Committee (New South Wales, 
Australia) and the Nelson Mandela 
Medical School Ethics Committee 
(KwaZulu-Natal, South Africa).
Results
Supply data
Fig. 1 shows the anti-hypertensives sup-
plied over a 6-month period. Hydrala-
zine and prazosin represented less than 
2% of all the anti-hypertensive medica-
tions supplied, and data for these drugs 
are not shown separately in the figure. 
Diuretics were the most commonly 
supplied anti-hypertensive agents at 40 
hospitals (74%) in the province. The 
average relative supply of diuretics in 
the province was 42%, with hydrochlo-
rothiazide being the most commonly 
supplied. Diuretics are also used to treat 
conditions other than hypertension.
ACE inhibitors were the second 
most commonly supplied drugs in the 
province. At 14 hospitals (26%), ACE 
inhibitors were supplied more often 
than diuretics. The average relative 
supply of ACE inhibitors was 27%; 
Fig. 1. Relative proportions of anti-hypertensive drugs supplied to 54 hospitals in 
KwaZulu-Natal, South Africa, over a 6-month period
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Fig. 2. Mean number of anti-hypertensive drugs in each group, per 100 prescriptions, 
in 16 hospitals in KwaZulu-Natal, South Africa
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However, ACE inhibitors may also be 
prescribed for conditions other than 
hypertension.
The average relative supply of 
methyldopa was 10%. However, there 
was significant variation between hos-
pitals, from 0% to 37%. Reserpine rep-
resented 7% of all the anti-hypertensive 
drugs supplied in all the hospitals. Its 
supply was high only in two hospitals, 
where it represented 20% and 40% of 
all the anti-hypertensive medications 
supplied. Because reserpine is used only 
to treat hypertension, these supply data 
accurately reflect the number of patients 
with hypertension who received the 
drug. Calcium channel blockers and 
beta blockers each represented 6% of 
all anti-hypertensives supplied. The 
most commonly supplied beta blocker 
was atenolol. However, there appeared 
to be no preferred agent among the 
calcium channel blockers; amlodipine, 
isradipine and nifedipine were sup-
plied in roughly the same proportions. 
Hydralazine represented less than 5% 
of all the anti-hypertensive drugs sup-
plied at all hospitals except one, where 
it represented 11%.
Prescription survey
Fig. 2 shows the average number of 
anti-hypertensive drugs prescribed by 
class per hundred prescriptions. We 
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noted substantial differences in meth-
yldopa use between hospitals: the per-
centage of prescriptions for methyldopa 
ranged from 0% to 37%. Of the 1600 
prescriptions surveyed, 152 included 
methyldopa (9.5%).
Although reserpine is the preferred 
second-line treatment in the guidelines, 
we noted this drug was rarely pre-
scribed, with only 84 prescriptions in 
total (5.3% of all prescriptions). Three 
hospitals with the highest rates of reser-
pine prescription accounted for 56% 
of reserpine use overall. In 6 hospitals 
reserpine was not prescribed at all.
Monotherapy and combination 
therapy
Most patients (51–91%) were pre-
scribed combination therapy for un-
complicated essential hypertension. The 
mean number of items per prescription 
was 1.95. Approximately 63% of the 
patients on monotherapy were pre-
scribed a diuretic; 19%, an ACE inhibi-
tor; 8% a calcium channel blocker, and 
7%, a beta blocker. Overall, only 1% of 
patients were prescribed methyldopa or 
reserpine as monotherapy.
Comparison of supply data and 
prescription survey
Supply data were available for the 54 
hospitals in the supply study and for the 
16 hospitals that also took part in the 
prescription survey. Table 1 shows drug 
groups ranked in order of actual relative 
use (calculated using supply data as well 
as data from the prescription survey) 
Table 1.  Compared results of using supply data and a prescription survey for 
measuring anti-hypertensive drug use in hospitals in KwaZulu-Natal, South 
Africa
Actual or 
suggested use
Treatment guidelines Supply data Prescription survey
(%)a (%)a
1st line Diuretic (HCT) Diuretic (42) Diuretic (43.5)
2nd line Reserpine ACE inhibitor (27) ACE inhibitor (29.5)
3rd line Beta blocker Methyldopa (10) CCB (12.4)
4th line ACE inhibitor Reserpine (7) Beta blocker (6.7)
5th line CCB Beta blocker (6) Methyldopa (4.9)
6th line Alpha blocker CCB (6) Reserpine (2.7)
7th line – Hydralazine (1) Hydralazine (0.2)
ACE, angiotensin-converting enzyme; CCB, calcium channel blocker; HCT, hydrochlorothiazide.
a  The percentages in parentheses represent the proportion of all anti-hypertensive drugs supplied or 
prescribed.
Table 2.  Total cost of anti-hypertensive drugs in 16 hospitals in KwaZulu-Natal, 
South Africa, based on hospital prescription practices, versus total cost had 
hypertension treatment guidelines been followed
Anti-hypertensive 
drug
Cost
(in US$a, per 100 prescriptions)b
Under current practice Under treatment guidelines
Diuretic 27.20 27.20 (1st line)
ACE inhibitor 67.25 15.07 (4th line)
CCB 86.33 57.55 (5th line)
Beta blocker 6.05 11.16 (3rd line)
Methyldopa 20.61 –
Reserpine 5.15 59.68 (2nd line)
Hydralazine 0.724 –
Total 213.30 170.67
ACE, angiotensin-converting enzyme; CCB, calcium channel blocker.
a  1 United States dollar (US$) = 10 South African rands.
b  A prescription for a single patient may contain one or more drugs.
and suggested relative use, as recom-
mended by the national guidelines.
Costs of actual practice versus 
guideline recommendations
We used results of the prescription sur-
vey and information from the PMSC 
price list to calculate the cost of a 
1-month supply of anti-hypertensive 
drugs for 100 patients. We also cal-
culated the total expenditure had 
treatment been given in accordance 
with standard treatment guidelines. To 
perform this calculation we assumed 
that the proportions of second-, third-, 
fourth- and fifth-line anti-hypertensive 
drugs prescribed, as determined from 
the prescription survey, would be 
identical irrespective of the agent that 
had been used. Actual costs were 19% 
greater than would have been the case if 
standard treatment guidelines had been 
followed (Table 2).
Discussion
Evaluating the success of a national 
drug policy always calls for assessing 
prescription practices through appro-
priate measurements, but poor data 
availability may be a limiting factor 
in resource-poor countries. Therefore, 
it is important to establish whether 
surrogate measures, such as drug sup-
ply data, can be used where routinely 
measuring prescription data is impos-
sible. Our results confirm that supply 
data are relatively easy to obtain and 
yield a broad pattern of use that closely 
resembles the pattern revealed by direct 
observation. However, discrepancies 
were noted in the estimated use of some 
groups of medicines, and several factors 
could account for this.
First, “losses” occurred in the sup-
ply data study because some of the 
medicines either expired, were stolen 
or were used for conditions other than 
hypertension. Such losses would not 
have been captured by the prescription 
survey. Second, our prescription survey 
was conducted in only a subset of hospi-
tals, since it was not feasible to perform 
prescription studies in the 54 hospitals 
included in the supply data study. 
Third, supply data were obtained for a 
6-month period, whereas the hospital 
prescription surveys took place on a 
single day. Variation over these unequal 
periods possibly accounts for some dif-
ferences, even though one indicator 
– the proportional use of methyldopa 
– had been stable over almost 2 years 
before the study started.
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Our main conclusions based on 
supply data study and the results of the 
prescription survey are the same. Diuret-
ics and ACE inhibitors are the two 
most frequently supplied or prescribed 
drugs for essential hypertension. All 
other anti-hypertensive agents are used 
much less frequently, although the two 
measurement methods do not yield the 
same relative order of use. As methyl-
dopa is not listed in the hypertension 
guidelines for any indication other 
than gestational hypertension, any use 
outside of pregnancy is inappropriate. 
Both measurement methods identify 
high rates of methyldopa prescription as 
a problem. Likewise, reserpine is recom-
mended in the guidelines as second-line 
therapy but is clearly not being used as 
such, and the recommended third-line 
drugs, the beta blockers, are also used 
less than expected.
To determine whether the guide-
lines for the treatment of hypertension 
are being followed, initial supply data 
are as useful as more time-consuming 
and labour-intensive prescription sur-
veys. They might serve to indicate, at 
least, whether more precise and focused 
drug utilization studies are required to 
identify lack of adherence to specific 
recommendations.
Our findings reinforce those of 
earlier studies 2–4 that hypertension 
guidelines were not being followed in 
some health settings. Reasons for this 
non-adherence can only be ascertained 
through a qualitative study. Finally, 
it is of interest that the costs of drug 
treatment were calculated to be higher 
by 19% than would have been the case 
if national guidelines had been fol-
lowed.  ■
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Résumé
Comparaison de deux méthodes pour mesurer l’utilisation des médicaments antihypertenseurs : conformité 
de l’utilisation avec les directives thérapeutiques standard sud-africaines
Objectif Evaluer l’observation par les prescripteurs des directives 
thérapeutiques standard dans l’utilisation des antihypertenseurs 
en Afrique du Sud, déterminer si les données de délivrance sont 
des indicateurs utiles de l’usage de ces médicaments et estimer 
les conséquences en termes de coût du non-respect des directives 
standard.
Méthodes Nous avons entrepris deux études : une analyse des 
enregistrements de médicaments antihypertenseurs délivrés aux 
54 hôpitaux publics de KwaZulu-Natal disposant d’une consultation 
d’hypertension et une enquête par observation directe des prescriptions 
d’antihypertenseurs présentées en pharmacie, effectuée sur un sous-
groupe d’hôpitaux comprenant 16 des 54 hôpitaux susmentionnés. 
Nous avons calculé l’utilisation de chaque groupe d’antihypertenseurs 
en proportion de l’ensemble des antihypertenseurs délivrés ou 
prescrits. Nous avons classé les groupes de médicaments en vue 
d’établir des comparaisons avec les directives thérapeutiques standard 
sud-africaines et nous avons confronté les proportions obtenues à 
partir des données de délivrance et celles déterminées à partir de 
l’enquête sur les prescriptions.
Résultats Les données de dél ivrance ont montré que, 
conformément aux directives thérapeutiques, les diurétiques et 
les inhibiteurs de l’enzyme de conversion de l’angiotensine étaient 
les médicaments les plus fréquemment prescrits (42 et 27 % 
respectivement). Néanmoins, la méthyldopa - non préconisée par 
les directives thérapeutiques - représentait 10 % de l’ensemble 
des antihypertenseurs délivrés, avec de grandes variations entre 
les hôpitaux (0 à 37 %). La réserpine, médicament de deuxième 
choix selon les directives thérapeutiques, était employée en grandes 
quantités par deux hôpitaux seulement. Les agents bloquants des 
canaux calciques et les bêta-bloquants représentaient une faible 
proportion des antihypertenseurs délivrés : 6 % pour chacune de 
ces catégories. Les résultats de l’enquête sur les prescriptions étaient 
en accord avec les données de délivrance à propos des médicaments 
les plus prescrits, mais donnaient des estimations légèrement 
différentes pour l’utilisation des autres groupes.
Conclusion Les données de délivrance, source la plus facilement 
disponible d’informations sur l’utilisation des médicaments dans 
les pays en développement, constituent (avec quelques réserves) 
une source de données fiable pour l’évaluation de l’observation 
des directives thérapeutiques. Nos résultats mettent en évidence 
un non-respect substantiel de ces directives.
Resumen
Comparación de dos métodos para medir el uso de los antihipertensores: concordancia del uso con las 
directrices terapéuticas sudafricanas
Objetivo Determinar la observancia de las directrices sudafricanas 
sobre el tratamiento antihipertensor por parte de los prescriptores, 
determinar si los datos sobre el suministro son indicadores útiles 
del uso de los fármacos, y evaluar las repercusiones de la no 
observancia de las directrices en el costo del tratamiento.
Métodos Realizamos dos estudios: un análisis de los registros 
de los antihipertensores suministrados a 54 hospitales del 
sector público de KwaZulu-Natal que disponían de consultas de 
hipertensión, y una observación directa de las prescripciones de 
antihipertensores presentadas a las farmacias en 16 de esos 
54 hospitales. El uso relativo de cada antihipertensor se calculó 
como la proporción con respecto a todos los antihipertensores 
suministrados o prescritos. Los grupos de fármacos fueron 
ordenados por frecuencia de uso para compararlos con las 
directrices terapéuticas sudafricanas. También se compararon los 
resultados proporcionados por los estudios del suministro y de las 
prescripciones.
Resultados Los datos sobre el suministro revelaron que, 
de acuerdo con las directrices terapéuticas, los fármacos 
suministrados con más frecuencia fueron los diuréticos y los 
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inhibidores de la enzima de conversión de la angiotensina (42% 
y 27%, respectivamente). Sin embargo, la metildopa, que no está 
incluida en las directrices terapéuticas, representó un 10% de las 
totalidad de los antihipertensores suministrados, aunque hubo 
una gran variabilidad entre hospitales (0 a 37%). La reserpina, un 
tratamiento de segunda elección según las directrices, sólo era 
muy utilizada en dos hospitales. Los bloqueantes de los canales 
del calcio y los betabloqueantes representaron una pequeña 
proporción de la totalidad de los antihipertensores suministrados 
(6% cada uno). Los resultados del estudio sobre las prescripciones 
fueron concordantes con los del suministro con respecto a los 
antihipertensores prescritos con más frecuencia, pero presentaron 
ligeras diferencias con respecto al uso de otros fármacos.
Conclusión Los datos sobre el suministro, que son los más fáciles 
de obtener para determinar el uso de los fármacos en los países 
en desarrollo, constituyen (con algunos condicionamientos) una 
fuente de información fiables para evaluar la observancia de 
las directrices terapéuticas. Nuestros resultados muestran una 
inobservancia considerable de las directrices terapéuticas.
صخلم
ايقيرفأ بونج في ةيرايعلما ةجلاعملل ةيداشرلإا لئلادلا عم مادختسلاا قفاوت :طغضلل ةضفاخلا ةيودلأا مادختسا سايقل ينتقيرط ينب ةنراقم
 ةيداشرلإا لئلادلاب طغضلل ةضفاخلا ةيودلأا فصي نم لاثتما مييقت :فدهلا
 تناك اذإ ام لىع فرعتللو ،ايقيرفأ بونج في ةيودلأا كلتب ةجلاعملل ةيرايعلما
 مييقتلو ،اهمادختسلا ًاديفم ًاشرؤم دعت ةيودلأا كلتب دادملإا لوح تايطعلما
.ةيداشرلإا لئلادلا كلتل لاثتملاا مدع دنع فيلاكتلا يرثأت
 يتلا  طغضلل  ةضفاخلا  ةيودلأا  تلاجسل  ًلايلحت  ؛ينتسارد  انيرجأ  :ةقيرطلا
 طغض  عافترا  ةجلاعلم  ةدايع  عم  ماعلا  عاطقلا  نم  ىفشتسم  54  اهب  دوز
 ةضفاخلا  ةيودلأا تافصول ةشرابلما ةبقارملل  ًاحسمو ؛لاتان  ولوزاوك في مدلا
 ىفشتسم 16 نم فلأتت ةيعرف ةعومجم في ةلدايصلا لىإ درت يتلا طغضلل
 ةعومجم لكل يبسنلا  مادختسلاا  انبسح دقو .54  ـلا  تايفشتسلما  ينب نم
 ةيودلأا  عيمج  لىإ  ةيوئم  ةبسنك  طغضلل  ةضفاخلا  ةيودلأا  تاعومجم  نم
 ًاقفو ةيودلأا تاعومجلم ًابيترت انيرجأو .فصوت وأ درت يتلا طغضلل ةضفاخلا
 كلتب ةجلاعملل ةيرايعلما ةيداشرلإا لئلادلاب اهتنراقم ضرغب اهمادختسا ىدلم
 تايطعم  نم  ةقتشلما  ةيوئلما  بسنلا  انراق  ماك  ،ايقيرفأ  بونج  في  ةيودلأا
 فصو  لوح  هانيرجأ  يذلا  حسلما  نم  ةقتشلما  ةيوئلما  بسنلا  عم  دادملإا
.ةيودلأا كلت
 لئلادلا  عم  شىماتت  اهنأ  ةيودلأاب  دادملإا  تايطعم  ترهظأ  :تادوجولما
 بلاقلا  ميزنلإا  تاطبثمو  تاردلما  تناك  دقف  ،ةجلاعملل  ةيداشرلإا
 ليثلما نأ لاإ ؛)لياوتلا لىع 27و %42( ًادادمإ ةيودلأا ثركأ يه ينسنتويجنلأل
 لمجم  نم  %10  لّثم  دقو  ،ةجلاعملل  ةيداشرلإا  لئلادلا  في  جردي  لم  ابود
 ًاعساو ًافلاتخا فلتخت ةيوئلما هتبسن نأ لاإ ،طغضلل ةضفاخلا ةيودلأا دادمإ
 نم نياثلا  طخلا  لثيم يذلا  ينبرزرلا  امأ  .)%37-%0(  رخآو ىفشتسم ينب
 تلّثم مايف .طقف يننثا ينيفشتسم في ةيربك تايمكب مدختسا دقف تارايتخلاا
 ةليئض ةيوئم ةبسن ةيناينبلا تلابقتسلما تاصراحو مويسلاكلا تاينق تاصراح
 تناك دقو .اهنم لكل %6 زواجتت ملف ،طغضلل ةضفاخلا ةيودلأاب دادملإا نم
 دادملإا تايطعم عم ةيشماتم تافصولا حسم نم اهيلع انلصح يتلا جئاتنلا
 ًافيفط ًافلاتخا ةفلتخم تاريدقت تطعأ اهنكلو ةفوصولما ةيودلأا مظعم في
.ىرخلأا ةيودلأا مادختسا لوح
 لوح ةحاتإ تامولعلما رداصم ثركأ ةيودلأاب دادملإا تايطعم دعت :جاتنتسلاا
 )تاطايتحلاا  ضعب  ذاختا  عم(  يهو  ،ةيمانلا  نادلبلا  في  ةيودلأا  مادختسا
 .ةجلاعملل ةيداشرلإا لئلادلل لاثتملاا مييقت لوح تامولعملل ةقوثوم رداصم
 لئلادلل لاثتملاا مدع نم ًاماه ًاردق اهيلإ  انلصوت يتلا  جئاتنلا  ترهظأ دقو
.ةجلاعملل ةيرايعلما ةيداشرلإا
